Stand up Chuck. Let 'em see you.
Oh, god love ya, what am I talking about.
Posted on 10/06/2021 11:45:23 AM PDT by Red Badger
Preserving the blood-brain barrier might prove to be an effective way of preventing the onset of Alzheimer's disease
As researchers continue to search for the causes behind Alzheimer's disease and age-related dementia, one possibility is that a leaky blood-brain barrier could have a role to play, allowing for the easy passage of harmful proteins. A new study has explored how this defense might be shored up through the use of an existing anti-cancer drug, with the authors demonstrating some promising results around the reversal of cognitive decline in mice.
The blood-brain barrier is an almost impenetrable membrane that prevents harmful particles from entering, and is therefore key to maintaining the health of the organ and human body as a whole. One line of thinking when it comes to Alzheimer's disease is that a breakdown in this important barrier can allow proteins and fragments such as tau and beta-amyloid to enter, seeding toxic plaques associated with cognitive decline.
In recent years, studies have shown how these leaks could act as early warning signs for Alzheimer's, and how they allow blood-clotting proteins to enter the brain that cause damage to the synapses. One 2019 study even showed how an anti-inflammatory drug can counter the harmful effects of these invasive proteins and reverse cognitive decline associated with dementia in mice.
For this latest study, scientists at the University of British Columbia looked to build on some of their previous research demonstrating how these problematic leaks in the blood-brain barrier could be the result of proliferating blood vessels. This pointed them toward the idea that an agent that prevents irregular formation of blood vessels could put the brakes on this process, which in turn led them to an already-approved chemotherapy drug called Axitinib.
“Axitinib, the anti-cancer drug we used, blocks a receptor in the brain called a tyrosine kinase receptor, which is partly responsible for spurring blood vessel formation,” explained Dr. Chaahat Singh, the paper’s first author. “It stops abnormal blood vessels from growing, which then prevents many downstream effects.”
Working with mouse models of Alzheimer's, the scientists administered Axitinib over the course of a month and then used molecular analysis to study the effects on the rodents. This revealed a dramatic reduction in blood vessel growth, leakage of the blood-brain barrier and formation of amyloid plaques. Assessments were then carried out to assess the cognition and memory of the mice, including maze tests and fear and conditioning tests, which showed profound reductions in cognitive impairment.
“We are really very excited, because these findings suggest we can repurpose approved anti-cancer drugs for use as treatments for Alzheimer’s disease,” says Professor Wilf Jefferies, the study’s senior author. “It could shorten the clinical development by years.”
It is important to note that this research is still in its very early stages. More study is required to ascertain the safety of subjecting older subjects to a long-term Alzheimer's treatment regime involving a chemotherapy drug. And that's if these results can be translated from mice to humans in the first place.
Despite these sizable "ifs" the results are promising in that they further highlight the potential of an alternative pathways to tackle Alzheimer's. Many clinical trials have involved drugs designed to take out harmful brain plaques as a way of treating Alzheimer's, and almost all have failed in clinical trials. Studies such as this one add weight to the idea that the disease could be treated in other ways.
“Researchers including myself have been disappointed in observing numerous clinical trials for Alzheimer’s disease fail to reach their clinical endpoints,” says Jefferies. “The therapeutic approach we discovered has an opportunity to revise the clinical treatment of Alzheimer’s patients, which I think is absolutely needed at this point for the field to advance.”
The research was published in the journal EBioMedicine.
Source: University of British Columbia
Too bad it can’t actually be used to treat alzheimers since that wasn’t its intended original use and I think they do use it for cancer in animals as well
Stand up Chuck. Let 'em see you.
Oh, god love ya, what am I talking about.
Nope...can’t use it...its for cancer...and you ain’t got cancer. Sorry...
You masses can’t use it because it means you will live longer and become a burden on society. Plus, you’ll bankrupt Social Security. We need that money to fill up our trough.
That goes along with the scientist that discovered bacteria in Alzheimer plaques. His mentor was the dentist that discovered bacteria caused ulcers.
“Nope...can’t use it...its for cancer...and you ain’t got cancer. Sorry...”
That principle applies only to medicines that cure COVID but are approved for other applications.
Wrong. FDA-approved medications can be legally prescribed for off label use.
Axitinib has been approved by the FDA, so it can be legally prescribed by a physician.
it was a sarcasm post i.e. ivermectin, HCQ
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.